China SXT Pharmaceuticals, Inc. (SXTC) — key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2024)

$1.7M

Net Income/Loss (FY2024)

-$3.3M

Total Assets (FY2024)

$21.7M

Total Equity (FY2024)

$15.4M

Cash Flows from Operating Activities (FY2024)

-$2.3M

Source: China SXT Pharmaceuticals, Inc. 20-F filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.